Guangdong Pharma Univ. FXR compound 19

Guangdong Pharma Univ. FXR compound 19: sourced facts only. name: "In this study, the structure-based scaffold hopping strategy was performed by hybrid FXR agonist 1 and T0901317, which resulted in the discovery of sulfonamide FXR agonist 19." [PMID:37413879]; target: "In this study, the structure-based scaffold hopping strategy was performed by hybrid FXR agonist 1 and T0901317, which resulted in the discovery of sulfonamide FXR agonist 19." [PMID:37413879]; developer: "School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China." [PMID:37413879]; stage: "In NASH model, compound 19 alleviated the typical histological features of fatty liver, including steatosis, lobular inflammation, ballooning, and fibrosis." [PMID:37413879]